Ten years of PAM: Cases, Laboratory Protocols and Therapeutic Approaches

Giovanni De Jesus Milanez*
Department of Medical Technology, Far Eastern University, Manila, PHILIPPINES.
Submission Date: 15-09-2019; Revision Date: 11-11-2019; Accepted Date: 16-12-2019

ABSTRACT
Primary Amoebic Meningoencephalitis (PAM) is considered as one of the health challenges in the medical field due to its fatal outcome to the host. This condition is caused by infection of the protozoan Naegleria fowleri. Since the time of its description in 1965 by Fowler and Carter, there are only approximately 250 cases reported worldwide and almost 90% of these cases have a fatal outcome. Its rare occurrence and difficulty in diagnosing makes it a considerable public health concern. This review aims to at least provide an update on the current cases, strategies and therapeutic approaches in the treatment and management of PAM in the health care setting in the last ten years (2008-2018). Due to the rare occurrence of the condition, a total of only 45 related articles using the PubMed database were included in this review. Key words used to come up with this review included “Naegleria”, “therapeutic approach”, “Primary Amoebic Meningoencephalitis” and “cases”. Studies which include the isolation of Naegleria spp from environment sources as well as non-human occurrences were excluded from this review. From the investigated studies from the source database, 1 out of 12 or 8.3% of PAM cases had a positive outcome where the patient had complete recovery from the condition. Although majority of cases underwent almost the same combination therapeutic regimen which includes amphotericin B and rifampicin, it seems that the key to complete recovery from this condition is the efficiency of the diagnostic procedure given to the patient by clinicians.

Key words: Amphoteric B, Free living amoebae, Naegleria sp., PAM, PCR.

INTRODUCTION
Primary Amoebic Meningoencephalitis (PAM) is a fatal central nervous system condition caused by the amoeb-flagellate Naegleria fowleri. This amphizoic organism was first described by Fowler and Carter in 1965 involving 4 cases of severe meningitis in Australia.[1] Since its description, occurrence of this fatal condition has been known globally.[2] There are only approximately, 250 reported cases of PAM around the world and survival rate of infected individuals are considered low. Naegleria sp. can be separated from the other parasitic free-living amoebae by its ability to exist in three morphologic forms: Cystic, trophozoite and flagellated forms. The trophozoite form is considered as the infective stage and responsible for the development of this condition in the human host. This life stage of the organism along with the other forms is present in freshwater lakes, swimming pools and recreational hot springs.

The course of infection of Naegleria fowleri begins when the organism gains access to the nasal epithelium through accidental inhalation of water positive with trophozoites.[1] The trophozoite then uses the olfactory bulb as route and crawls up the olfactory nerve from which they cross the cribiform plate to reach the neuroepithelium where it induces a lytic necrotic hemorrhage of brain tissues.[3] The parasite is able to cause tissue destruction by secreting elastase, a proteolytic enzyme believed to be attributed to the organisms virulence.[4] The course of infection of PAM is fast and may be complete and fatal in a span of 5-7 days upon onset.
of symptoms with no medical intervention.\textsuperscript{[9]} Due to the rapid onset of the disease, there is no ample time for the body to react immunologically via the humoral immune response. Moreover, the lack of distinct symptomatology of this condition poses several challenges to clinicians in providing definitive diagnosis in the early onset of infection since PAM greatly resembles bacterial and viral meningitis symptoms such as: high fever, nuchal rigidity, a positive Kernigs and Brudzinsky sign, nausea and vomiting.\textsuperscript{[3]} The history of having contact with fresh water proves to be valuable information in the early diagnosis of PAM and may be instrumental in providing an effective therapeutic regimen. Unfortunately, medical protocols would tend to oversee this piece of information especially when presented by general symptoms that most often would lead clinicians to suspect bacterial or viral meningitis instead of the protozoan form.

MATERIALS AND METHODS

This review has been conducted by compiling documented cases of PAM through PubMed search engines database from 2008 to 2018. Search keywords included “Naegleria”, “therapeutic approach”, “primary Amoebic Meningoencephalitis” and “cases”. Due to the rare occurrence of this condition only 45 articles matched the search but only 22 are considered in this review. Also included in the study are approaches in therapeutic regimen given to patients as well as the possible laboratory methods that can be provided to patients for faster identification of the organism. Articles that involved PAM cases from non-human sources as well as answers to scientific quizzes and questions as well as isolation of Naegleria spp. from environmental sources were excluded from the study.

RESULTS

Epidemiology and Reported Cases of PAM (2008 – 2018)

Although Naegleria fowleri is considered to be widespread along with other free-living amoebae in the environment, cases concerning PAM are still considered a rare medical condition. In fact, from its first description in 1965, there are only an estimated 300 cases worldwide, 111 cases from this figure are coming from the United States.\textsuperscript{[6]} Due to its rarity in the clinical setting, familiarity of microscopist to the parasite causing PAM is considered a major pitfall in the successful early diagnosis of this condition. In the last decade, there are 12 cases of PAM worldwide. Three (25\%) of these cases came from the US\textsuperscript{[7,8]} and have occurred during the summer months. Table 1 shows PAM cases per country as well as the therapeutic regimen given to patients. Gathered data suggested that cases are spread out across age groups and that majority of people who contracted this organism had a history of swimming in infected waters. Although other forms of infection routes should be considered based on cases that does not involve contact with water. Furthermore, geographically speaking, case incidences of infection are still limited to countries that are known to have a temperate climate which reinforces the organisms’ thermophilic nature.

Microscopy

Due to the rapid onset of PAM and its fatal outcome, the early diagnosis of this condition is vital for the survival of the patient suffering from this condition. Although neurological symptoms and a history of exposure to Naegleria fowleri-infested freshwater may provide a vital piece of information for early diagnosis, this, however may prove inconclusive for PAM infection. The manifestation of motile trophozoite stained with Trichrome or Giemsa stain in wet mount preparations of cerebral spinal fluid may be considered as the method of choice for early diagnosis of PAM.\textsuperscript{[4]} This method, however, requires a great deal of skill on the microscopists part in accurately differentiating trophozoites from WBC’s (mostly PMNS) especially when the trophozoite count is low in CSF specimens.

Culture Methods

The use of Non nutrient agar lawn with either live or killed Escherichia coli and media containing low nutrient concentrations proved to be an effective way to grow and isolate FLAs which include Naegleria sp. Although other choice of bacteria as food source is not exclusive to the organism, it is however important to consider to select non mucoid strains of bacteria since the presence of mucoid capsule inhibits phagocytosis of growing trophozoites and eventually affects further proliferation of FLAs in the culture medium.

Analysis of Cerebrospinal Fluid

Although the absence of active trophozoite may be unlikely, correlation of CSF chemistry results such as an elevated protein level (100-1000 mg/dl), an elevated CSF pressure (up to 600 mm H\textsubscript{2}O), an elevated RBC and WBC counts (up to 26,000 mm\textsuperscript{3}/ml) and low CSF glucose levels (< 10 mg/dl) may prove to be helpful in suspecting possible infections.\textsuperscript{[4]}

98 Asian Journal of Biological and Life Sciences, Vol 8, Issue 3, Sep-Dec, 2019
Development of Microscopic Methods

The development of microscopic methods such as the use of Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM) in identifying FLAs has been instrumental in understanding the different mechanisms involved in the direct effects of several experimental drugs to different forms of the organism. Several studies have used the efficiency of SEM to described structural damage of certain micro-organisms to the cellular integrity of the cyst wall of test FLAs. Furthermore, the use of high level magnification microscopy such as SEM and TEM has helped researchers through the years to differentiate structural differences from one species to another in a microscopic level. These developments have further helped both researchers and clinicians alike in developing therapeutic regimens to patients suffering from amoebic encephalitis by formulating effective anti-amoebicidal drug targeting vulnerable structures of the organism.

Successful therapeutic approaches against PAM

Due to the severity and fatal outcome of the disease process of PAM, several experimental drugs have been tested in vitro to effectively kill the protozoan inside the host it infects. Also, early diagnosis and aggressive treatment appears to be the common key in the treatment regimen provided to patients who contracted this organism. It appears that the combination therapy of Amphotericin B, Rifampicin and antifungal drugs are the most common drug therapy given to patients suffering from PAM. Although administration of these drugs to patients will not assure survival, they are still considered the primary therapeutic regimen so far in the treatment of PAM in the clinical setting.

For this reason, several experimental treatment drugs have been used and have been added to the conventional combination drug therapy being administered to patients with PAM. One of the promising drugs includes miltefosine. In three cases of patients suffering from PAM, an anti-leishmania drug known as miltefosine was administered, two of the three patients managed to survive, with one patient undergoing full recovery from the disease. Although the exact effect of the drug to Naegleria sp. has not been further studied, miltefosine in combination with other therapeutic drugs such as Amphotericin B, Rifampicin, fluconazole and chlorpromazine has been proven effective both in vivo mouse models and in vitro studies.

In another study, the antirheumatic drug auranofin has been tested with axenic cultures of pathogenic strains of Naegleria fowleri and have been found to have amoebicidal effect on the protozoan resulting to the decreased
amoeba count in the cultures taking into consideration the effects of auranofin to the integrity of the protozoan membrane and decreases metabolic activity of the organism.[20]

Corifungin is another drug that has been proven to be more effective than Amphotericin B when it was tested in parallel with the latter drug both in vitro and in mice models. The effects of corifungin is mainly on disruption of cytoplasmic and plasma membranes of the organism leading to complete lysis of the amoebae. More so, configurin has been approved by the FDA as an orphan drug for the treatment of PAM in the United States.[21]

| Table 1: Documented PAM cases, profile of patients, therapeutic regimen given and outcome for the last 10 years (2008-2018). |
|---|---|---|---|---|---|---|
| Country | Age of Patient | Gender | Year | Transmission to Host | Method of Diagnosis | Therapeutic Regimen | Outcome |
| India | 6 month old | M | 2010 | Well water used to bathe child - negative when sampled and cultured | Blood Chemistry, Hematology Testing, HIV testing, CSF wet mount, | Diazepam - Seizures, Amphotericin B, Chloramphenicol, Metronidazole | Dead |
| India | 20 yr old | M | 2009 | No history of swimming | CT scan, Blood count, CSF test | Amphotericin B and Rifampicin | Dead after 16 days Alive |
| Iran | 5 month old | M | 2012 | No history of swimming | CBC, CT, CSF wet mount (initial test negative for amoebae) | Vancomycin and Cetiriaome (bacterial meningitis), Amphotericin B and Rifampicin | Dead in 6 days |
| Costa Rica | 11 year old | M | 2014 | Swimming in hot spring and pond | CSF wet mount | None | Dead after 72 hr |
| Venezuela | 33 year old | M | 2008 | Swimming in fresh water bathe hole | CSF wet mount | None | Dead after 72 hr |
| Pakistan | 24 year old | M | 2009 | Swimming | CT scan, CSF wet mount 1(neg), CSF wet mount 2 | Ceftriaome and acyclovir - initial, not vancomycin and meropenem, Amphotericin B | Dead in 6 days |
| Pakistan | 30 year old | M | 2009 | Swimming | CT scan, CSF wet mount 1(neg), CSF wet mount 2 | Ceftriaome and acyclovir - initial, not vancomycin and meropenem, Amphotericin B | Dead in 8 days |
| Taiwan | 75 year old | M | 2013 | swimming in hot springs | CBC, Blood Chemistry, HIV test, MRI, CT scan, CSF wet mounts | Amphotericin B | Dead after 21 days |
| Zambia | 24 year old | M | 2017 | Swimming in River | Test for Malaria, CSF mounts (negative twice, third time on 8 day positive), CT normal | Cephrtriaome, Amphotericin B | Dead on 8th day |
| United States | 7 years old | F | 2010 | Swimming | CSF test, CT scan | Vancomycin and Cetiriaome (bacterial meningitis) | Dead |
| United States | 21 years old | F | 2015 | Swimming pool | CSF test (negative for trophozoites) | Vancomycin and Cetiriaome (bacterial meningitis) | Dead after 48 hr |
| United States | 4 year old | M | 2013 | Swimming | CT scan, CSF test | Vancomycin and Cetiriaome (bacterial meningitis) | Dead after 4 days |

**DISCUSSION**

Primary Amoebic Meningoencephalitis is considered a global concern due to the fatal outcome it has to
humans who get infected by the causative protozoan Naegleria spp. It has a global occurrence and considering that there are no concrete therapeutic regimen given to patients who fall victim to this condition makes it a public health concern. The difficulty to diagnose this condition may be due to lack of solid symptomatology which has led to several wrong treatment regimens given to patients which eventually lead to death of the host. The fast progression of the condition in the host has been a challenge not only to clinicians but more so to researchers who have tried to discover with either a faster and efficient diagnostic procedure or an effective treatment regimen to patients. Although PAM has a very low rate of incidence globally, it may have the highest rate in mortality compared with encephalitis of bacterial and viral in origin. For this reason alone that it should be considered as a priority in terms of discovering an effective treatment protocol.

In terms of diagnostic protocol, definitive microscopic identification of the parasite in the CSF seem to be the most reliable to make a definite diagnosis. Unfortunately, most of the time this microscopic examination is done only after eliminating the possibility of bacterial or viral meningitis thus leaving PAM untreated for some time. The use of CT scans and the like may not be so useful as well in providing diagnosis for people who contracted the parasite. Culture methods may take too long to provide results which may be too late for the patient. The discovery of therapeutic drugs may hold the key in solving the problem posed by PAM, however, host responses to certain drugs are different from another. One drug may prove to be effective to one patient but may prove ineffective to another. The response of the host to the aggressive drug treatment to PAM has been probably one of the greatest concerns to researchers and clinicians since these drugs have the same amoebicidal effect to the parasite and yet the outcome becomes different. Considering that all cases presented in this review has been given the same aggressive therapeutic regimen but the turnout of survival is low (1 out of 12 cases). There is, however, a link between the survival of the patient and the time the aggressive drug treatment is applied. This means that the early the clinicians can provide a definitive diagnosis for PAM, the sooner the drug administration can be done to the patient.

In short, clinicians may need to consider encephalitis caused by Naegleria sp in their routine medical history checks when faced with patients showing the same symptoms.

CONCLUSION

From the time of the discovery of Naegleria fowleri, researchers and clinicians have tried to come up with efficient methods in its faster diagnosis and effective therapeutic regimen. Although some therapeutic drugs are considered effective to some cases, this may not be the case for some as presented in this review. The challenge of formulating an effective therapeutic regimen and control for PAM is still a work in progress and researchers may still need to explore all possible niches to come up with one. The most effective however is the isolation of the organism from the source and share this information to the public so that measures from the health government may be established in areas where Naegleria sp. is present. Until the time that a vaccine or an effective drug is developed for PAM, the best way to keep us from contracting PAM is public health awareness.

ACKNOWLEDGEMENT

The author would like to thank the Department of Medical Technology, Far Eastern University for providing technical assistance in the completion of this review.

CONFLICT OF INTEREST

Author declare no conflict of interest.

REFERENCES


